Introduction
============

Diabetic retinopathy (DR) is a microvascular complication and is the most common cause of vision impairment and blindness among adults aged 20--74 years ([@b1-etm-0-0-4805]). The incidence of DR is associated with a number of risk factors such as hyperglycemia, hyperlipidemia and hypertension ([@b2-etm-0-0-4805]) and is characterized by signs of retinal ischemia and/or signs of increased retinal vascular permeability ([@b3-etm-0-0-4805]). Furthermore, DR is a progressive disease that endangers all retinal layers via insults of metabolic and neurological inflammation, which may contribute to vascular disruptions over time ([@b4-etm-0-0-4805]). Although clinical trials have demonstrated that effective treatments for diabetic retinopathy may reduce severe vision loss by 90% ([@b5-etm-0-0-4805]--[@b7-etm-0-0-4805]), these studies have emphasized the critical requirement for periodic eye examinations for all patients with diabetes. Thus, it is necessary to improve the means by which retinopathy is identified and prevented in its earliest stages rather than wait for the onset of vision-threatening lesions ([@b8-etm-0-0-4805]).

Over the past decade, studies have demonstrated that numerous factors may be involved in the pathogenesis of DR ([@b9-etm-0-0-4805],[@b10-etm-0-0-4805]) and it has been determined that chronic hyperglycemia is a factor involved in the development and progression of DR ([@b11-etm-0-0-4805]--[@b13-etm-0-0-4805]). Chronic hyperglycemia may induce multiple cellular changes that lead to diabetic complications due to its toxic effects and/or the effects of its pathophysiological derivatives that directly act on tissues ([@b14-etm-0-0-4805],[@b15-etm-0-0-4805]). Other factors including non-enzymatic glycation and glycoxidation may also induce DR. Furthermore, a number of candidate genes associated with the visual cycle, including lecithin retinol acyltransferase (LRAT) ([@b16-etm-0-0-4805]), retinal pigment epithelium (RPE)-specific protein 65 kDa (RPE65) ([@b17-etm-0-0-4805]) and 11-cis-retinoldehydrogenase (RDH5) ([@b18-etm-0-0-4805]) have been implicated in DR. Although early changes in retinal gene expression have been evaluated by analyzing retinal gene expression in streptozotocin (STZ)-induced diabetic rats ([@b19-etm-0-0-4805]), the specific underlying molecular mechanisms that occur during DR development and progression remain to be elucidated.

In the present study, bioinformatics was used to analyze the changes in retinal gene expression over a period of 12 weeks. Differentially expressed genes were analyzed at three different time points (1, 4 and 12 weeks) in the gene expression profile of retinal samples. The present study assessed the changes in retinal gene expression at the three time points with the aim of identifying the underlying molecular mechanisms of DR in diabetes.

Materials and methods
=====================

### Affymetrix microarray data of retina gene

The gene expression profile of GSE28831 was downloaded from the Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28831>). The dataset of GSE28831 was provided by a previous study by Kirwin *et al* ([@b19-etm-0-0-4805]), which obtained retinal samples of Long Evans rats, sacrificed 7 days, 4 weeks and 3 months after the induction of diabetes. A total of 21 retinal samples including 12 control samples and 9 diabetic samples were eligible for further analysis. Control samples consisted of 9 normal samples and 3 samples that received an injection of streptozotocin (STZ), but did not develop hyperglycemia. Diabetes samples included 9 retina samples which were obtained from STZ-induced diabetic rats. Retinal samples were collected from the retinas of control (n=3) and STZ-induced diabetic rats (n=3) at the three time points (1, 4 and 12 weeks after the induction of diabetes). In addition, 3 other samples were obtained from rats that were normoglycemic 1 week following STZ treatment that were used as normal controls.

The platform used was the GPL7294 Agilent-014879 Whole Rat Genome Microarray 4× 44K G4131F (Agilent Technologies, Inc., Santa Clara, CA, USA). The raw file and the annotation information file of the platform were also downloaded.

### Data preprocessing and differential expression analysis

Each probe was mapped with one or multiple gene names labeled in an annotation platform. To make statistical inferences, each gene was normalized between microarrays based on quartile normalization ([@b20-etm-0-0-4805]). When multiple probes were mapped to the same gene ID, the mean expression of those probes was calculated. When one probe was mapped to multiple gene sets, information about the probe was deleted. The linear models of microarray data (limma) package (Version 3.30.3; Bioconductor, Seattle, WI, USA) in R language was used to identify genes that were differentially expressed between control and disease samples at the three time points ([@b21-etm-0-0-4805]). The P values of genes were calculated using student\'s t test and adjusted by multiple testing to circumvent the false-positive results. Subsequently, the log2-fold-change (logFC) was calculated. Only genes with an adjusted P\<0.05 and \|log2FC\|\>1 were selected as differentially expressed genes (DEGs) ([@b22-etm-0-0-4805]), which were the signature genes of DR.

### Comparison of DEGs between control and disease samples

The DEGs between control and disease samples at the three time points were classified into upregulated and downregulated gene sets for further analysis. Subsequently, the contrast between the DEGs at the three time points was assessed according to the number of DEGs. Then gene sets at the three time points were compared and illustrated using a Venn diagram ([Fig. 1](#f1-etm-0-0-4805){ref-type="fig"}) ([@b23-etm-0-0-4805]).

### Principal component analysis (PCA) of DEGs

PCA, a multivariate regression analysis ([@b24-etm-0-0-4805]), was used to distinguish samples with multiple measurements ([@b25-etm-0-0-4805]). A PCA of DEGs was conducted in the present study using prcomp algorithm in R language ([@b26-etm-0-0-4805],[@b27-etm-0-0-4805]). A 3D graph was then obtained, in which DEGs were considered as variables and the difference between control and disease samples at the three time points were observed.

### Pathway enrichment analysis of DEGs

Pathway enrichment analysis is widely used to analyze high-throughput data and help link individual genes or proteins, which are differentially expressed under specific conditions, in order to improve understanding regarding biological pathways ([@b28-etm-0-0-4805]). To identify the pathways associated with DEGs selected at the three time points, the software tool KOBAS \[kyoto encyclopedia of genes and genomes (KEGG) Orthology Based Annotation System\] version 2 (<http://kobas.cbi.pku.edu.cn>), which was used for the annotation and identification of enriched pathways and diseases ([@b29-etm-0-0-4805]) based on the cumulative hypergeometric distribution algorithm (a discrete probability distribution), which was used for drawing from \>2 selections in a population, again without replacement ([@b30-etm-0-0-4805]) with P\<0.05 denoting a significant difference.

### Protein-Protein interaction (PPI) network construction

Numerous physical activities of the cells were evaluated based on protein integration and dissociation. A variety of cellular physiological activities and the reaction of cells to the external and internal environment are regulated by PPI networks ([@b31-etm-0-0-4805]). Thus, a more thorough investigation of protein interactions is required to understand this biological phenomenon ([@b32-etm-0-0-4805]).

STRING (search tool for retrieving interacting genes/proteins; <http://string-db.org/>) ([@b33-etm-0-0-4805]) provides uniquely comprehensive coverage and ease of access to experimental and predicted interaction information. A PPI network was constructed, in which the interactions of DEGs between control and disease samples at the three time points were mapped to STRING based on information including the sequence characters and structures. Interaction patterns with a combined score \>0.4 were selected. Subsequently, the PPI network at the three time points was visualized using Cytoscape software (version 3.4.0; Cytoscape Consortium, San Diego, CA, USA) ([@b34-etm-0-0-4805]). The nodes with higher degree served an important role in the PPI network, and may be the key nodes. Nodes represent the proteins encoded by DEGs, and a degree is considered to be the numbers of proteins that interact with that protein.

### Functional analysis of the DEGs at the three time points

Gene ontology enrichment analysis has been extensively used to provide a detailed view for understanding the molecular mechanism and identifying a deeply complicated network, which consisted of a set of genes with similar functions ([@b35-etm-0-0-4805]).

DAVID (a database for annotation, visualization, and integrated discovery; version 6.8; <https://david.ncifcrf.gov/home.jsp>) ([@b36-etm-0-0-4805]), a comprehensive set of functional annotation tools, was used for systematic and integrative analyses of large gene/protein lists. It evaluated the functions of the DEGs at the three time points and defined significant function enrichment of these genes in multiple gene ontology (GO) categories when P\<0.05.

Results
=======

### Identification of DEGs

A total of 402, 105 and 213 DEGs with the cut-off criteria of an adjusted value of significance (P\<0.05) and \|log2FC\|\>1 were selected as the thresholds to screen DEGs in control and disease samples at 1, 4 and 12 weeks.

### Comparison of DEGs at the three time points

As presented in [Fig. 1A](#f1-etm-0-0-4805){ref-type="fig"}, a total of 720 DEGs including 369 upregulated and 351 downregulated DEGs were screened. There were a greater number of downregulated than upregulated DEGs, with the exception of at 12 weeks following STZ-induced diabetes where the converse was true.

As presented in [Fig. 1B](#f1-etm-0-0-4805){ref-type="fig"}, there were no common DEGs at all three time points. However, there were 3 common DEGs in weeks 1 and 4, 17 common DEGs in weeks 1 and 12 and 10 common DEGs in weeks 4 and 12.

### PCA of DEGs

As presented in [Fig. 2](#f2-etm-0-0-4805){ref-type="fig"}, disease and control samples were completely separated by the selected DEGs at the three time points, meaning that the expression patterns of screened DEGs were specific at different time points and could be used to completely distiguish between disease and control samples.

### Pathway enrichment analysis of the DEGs

The significantly enriched pathways for the up- and downregulated DEGs are presented in [Table I](#tI-etm-0-0-4805){ref-type="table"}. There were two KEGG pathways (Neuroactive ligand-receptor interaction and Arachidonic acid metabolism) associated with DEGs at 1 week and one KEGG pathway (Retinol metabolism) associated with DEGs at 4 weeks. The retinol metabolism pathway included three downregulated genes (LRAT, RPE65 and RDH5) and the LRAT and RPE65 genes were also downregulated in DEGs at 12 weeks ([Fig. 3](#f3-etm-0-0-4805){ref-type="fig"}).

### PPI network construction

A total of 104, 22 and 35 PPI pairs at 1, 4 and 12 weeks, respectively were obtained. These PPI pairs were then used to construct the PPI network by integrating these associations in the retina ([Fig. 3](#f3-etm-0-0-4805){ref-type="fig"}). In this network, the proteins cytochrome P450 2B2 (CYP2B2; 1 week), mannan binding lectin-associated serine protease-2 (MASP2), LRAT, RPE65, RDH5 (4 weeks), mitogen-activated protein kinase 13 (MAPK13), LRAT and RPE65 (12 weeks) with high degrees form a local network and these proteins served an important role in the PPI network, and may be the key proteins in the development of DR.

### GO enrichment analysis of DEGs involved in PPI network

As presented in [Table II](#tII-etm-0-0-4805){ref-type="table"}, the DEGs in the PPI network at 1, 4 and 12 weeks were enriched in 12, 7 and 10 GO categories, respectively. Furthermore the DEGs in PPI network at 1 week were primarily enriched in processes associated with metabolism and response, including 'fatty acid metabolic processes', 'responses to drug' and 'responses to endogenous stimulus'. The DEGs in the PPI network at 4 weeks were enriched in processes associated with visual functions, such as 'visual perception', 'sensory perception of light stimulus' and 'vitamin A metabolic process'. The DEGs in the PPI network at 12 weeks were primarily enriched in regulatory processes including 'positive regulation of transcription, DNA-dependent', 'positive regulation of RNA metabolic process' and 'negative regulation of cell proliferation'.

Discussion
==========

Due to the increasing number of individuals diagnosed with diabetes, blindness caused by DR may become more common unless improvements are made in the diagnosis and treatment of DR ([@b7-etm-0-0-4805]). To improve understanding regarding the mechanisms involved in DR formation, the present study investigated the biological processes and signaling pathways associated with DR. The analysis of gene expression profiling identified the abnormally expressed genes associated with DR and enabled the identification of novel targets for therapeutic strategies. In the current study, a total of 402, 105 and 213 DEGs were screened at 1, 4 and 12 weeks, respectively, and eight significant genes were identified including CYP2B2 (at 1 week), MASP2, LRAT, RPE65, RDH5 (at 4 weeks), MAPK13, LRAT and RPE65 (at 12 weeks). Pathway enrichment and GO enrichment analyses revealed that DEGs were primarily enriched in processes associated with visual functions, including 'visual perception' and 'retinol metabolism' at 4 weeks.

CYP2B2 encodes an enzyme that controls arachidonic acid metabolism ([@b37-etm-0-0-4805]). Arachidonic acid is a precursor of inflammatory mediators, and early stage DR is regarded as a low-grade chronic inflammatory condition ([@b38-etm-0-0-4805]). Pathway enrichment analysis in the present study revealed that DEGs at 1 week were enriched in arachidonic acid metabolism. However, early inflammation of the eyes does not lead to any clinical manifestations. Therefore, inflammation in the retina may be an important component of early DR without clinical manifestations and the associated genes, including CYP2B2, may serve important roles in the evaluation of these functions. This is in accordance with a previous study by Joussen *et al* ([@b39-etm-0-0-4805]), which suggested that the response of the retina to the diabetic challenge consists of an inflammatory component.

In the present study, MASP2 was downregulated at 4 weeks. MASP2 encodes a novel serine protease that acts in the mannan-binding lectin (MBL)-lectin complement fixation pathway ([@b40-etm-0-0-4805]). The MBL-lectin complement fixation pathway is widely thought to serve a major role in host defense against infection and the expression of MBL is upregulated during inflammation ([@b41-etm-0-0-4805]). Østergaard *et al* ([@b42-etm-0-0-4805]) suggested that the complement system, specifically the MBL pathway, serves an important role in the pathogenesis of diabetic vascular complications such as DR. The decreased expression of MASP2 leads to MBL deficiency, which increases the overall susceptibility of an individual to infectious diseases ([@b43-etm-0-0-4805]). Thus, the present study suggests that the downregulation of MASP2 may stimulate the progression of DR and promote the appearance of other symptoms associated with DR.

LRAT, RPE65 and RDH5 are involved in retinol metabolism, and these genes are all part of the visual cycle that recycles all-trans-retinal from bleached photoreceptors to the 11-cis-retina required for phototransduction ([@b20-etm-0-0-4805]). The visual cycle is critical for visual function. Previous studies have reported that mutations in three different genes involved in the visual cycle, RPE65, LRAT and RDH12 cause early onset retinal dystrophy ([@b44-etm-0-0-4805]). Furthermore, RPE65 is essential for the maintenance of normal vision ([@b45-etm-0-0-4805],[@b46-etm-0-0-4805]). Thus, the downregulation of LRAT, RPE65 and RDH5 may lead to abnormal visual function. In addition, LRAT and RPE65 were included in the downregulated DEGs at 12 weeks and GO enrichment analysis revealed that he majority of DEGs at 4 weeks were associated with visual functions, including 'visual perception', 'sensory perception of light stimulus' and 'vitamin A metabolic process'. It has therefore been suggested that abnormal visual functions occur at 4 weeks in STZ-induced diabetic rats, which may be caused by the downregulation of genes associated with visual functions, including LRAT, RPE65 and RDH5. However, considering the present study is a bioinformatic study, further long-term studies are required to verify the association between gene expression and visual function.

MAPK13 encodes an enzyme that is included in the MAPK family. In the PPI network at 12 weeks, MAPK13 with a high degree formed a local network, suggesting that MAPK13 may serve a major role in DR. MAPKs have been implicated in a number of diseases including cancer, inflammatory disease, obesity and diabetes ([@b47-etm-0-0-4805],[@b48-etm-0-0-4805]). Previous studies have reported that MAPKs are involved in regulating insulin secretion and β cell survival ([@b47-etm-0-0-4805],[@b49-etm-0-0-4805],[@b50-etm-0-0-4805]) and MAPK inhibitors contribute to the prevention of cardiovascular diseases such as retinopathy ([@b51-etm-0-0-4805]). Therefore, MAPK13 may be involved in the pathogenesis of DR, although further studies are required to confirm this observation.

In conclusion, the data in the present study provide comprehensive bioinformatic analysis of DEGs, which may be involved in DR. It was also demonstrated that abnormalities in visual functions occur in STZ-induced diabetic rats at 4 weeks. DEGs, including CYP2B2, MASP2, LRAT, RPE65, RDH5 and MAPK13 may be potential targets for DR diagnosis and treatment. The results of the current study may provide a scientific basis for the diagnosis and targeted therapy of DR.
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![Protein-protein interaction network at the three timepoints. Network at (A) 1, (B) 4 and (C) 12 weeks. Green nodes represent proteins expressed by downregulated differentially expressed genes; red nodes represent proteins expressed by upregulated differentially expressed genes.](etm-14-03-2485-g02){#f3-etm-0-0-4805}

###### 

DEGs enriched in the KEGG pathway at the three time points.

  A, Week 1                                                                                                                                              
  --------------------------------------------------- ------- ------------------------------------------------------------------------------------------ ----------
  rno04080: Neuroactive ligand-receptor interaction   13      THRB, LEPR, VIPR1, NPY5R, CHRM5, GPR35, CHRM4, PTGDR, ADRA1B, MTNR1B, ADRA2B, HTR2A, GHR   0.005083
  rno00590: Arachidonic acid metabolism                 5     CYP2U1, CYP2B2, PLA2G4A, CYP4F17, GPX3                                                     0.048328
                                                                                                                                                         
  B, Week 4                                                                                                                                              
                                                                                                                                                         
  Term                                                Count   Genes                                                                                      P-value
                                                                                                                                                         
  rno00830: Retinol metabolism                        3       LRAT, RPE65, RDH5                                                                          0.041873

DEGs, differentially expressed genes; KEGG, kyoto encyclopedia of genes and genomes.

###### 

Enriched GO terms in the gene interaction network.

  A, Week 1                                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------
  GO:0010033 response to organic substance                                                                  CYP2B2, GATM, SI, RHOQ, ADH7, BRCA1, AFP, CCNE1, PLA2G4A, ABCB1B, APOA5, CYP2D4V1, RYR2, GNG5, CASQ1, SELE, NCOR2, PGGT1B, GHR   \<0.0001
  GO:0006631 fatty acid metabolic process                                                                   CYP2B2, LPL, PLA2G4A, CYP2D4V1, ADH7, BRCA1, SLC27A5, GHR                                                                        \<0.0001
  GO:0009725 response to hormone stimulus                                                                   CCNE1, CYP2B2, PLA2G4A, GATM, ABCB1B, APOA5, SI, RHOQ, GNG5, BRCA1, NCOR2, GHR                                                   \<0.0001
  GO:0009719 response to endogenous stimulus                                                                CCNE1, CYP2B2, PLA2G4A, GATM, ABCB1B, APOA5, SI, RHOQ, GNG5, BRCA1, NCOR2, GHR                                                   0.001969
  GO:0022602 ovulation cycle process                                                                        AFP, CCNE1, PLA2G4A, NPY5R, NCOR2                                                                                                0.002192
  GO:0042698 ovulation cycle                                                                                AFP, CCNE1, PLA2G4A, NPY5R, NCOR2                                                                                                0.002986
  GO:0042592 homeostatic process                                                                            LPL, JPH2, SMAD5, MBP, GCM2, PLA2G4A, HAMP, APOA5, KCNE1, RYR2, NCOR2, SASH3, HTR2A                                              0.003682
  GO:0019369 arachidonic acid metabolic process                                                             CYP2B2, PLA2G4A, CYP2D4V1                                                                                                        0.004721
  GO:0048878 chemical homeostasis                                                                           LPL, PLA2G4A, GCM2, JPH2, HAMP, APOA5, KCNE1, RYR2, NCOR2, MBP                                                                   0.006974
  GO:0042493 response to drug                                                                               CCNE1, CYP2B2, LPL, SNX27, ABCB1B, RYR2, SRD5A1, HTR2A                                                                           0.00758
  GO:0042304 regulation of fatty acid biosynthetic process                                                  PLA2G4A, APOA5, BRCA1                                                                                                            0.008354
  GO:0031099 regeneration                                                                                   AFP, CCNE1, NOTCH2, GATM, APOA5                                                                                                  0.008868
                                                                                                                                                                                                                                             
  B, 4 weeks                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                             
  Term                                                                                                      Genes                                                                                                                            P-value
                                                                                                                                                                                                                                             
  GO:0007601 visual perception                                                                              LRAT, RPE65, RGR, USH2A, RDH5                                                                                                    \<0.0001
  GO:0050953 sensory perception of light stimulus                                                           LRAT, RPE65, RGR, USH2A, RDH5                                                                                                    \<0.0001
  GO:0007600 sensory perception                                                                             LRAT, RPE65, RGR, USH2A, RDH5                                                                                                    0.0199
  GO:0050890 cognition                                                                                      LRAT, RPE65, RGR, USH2A, RDH5                                                                                                    0.029055
  GO:0006776 vitamin A metabolic process                                                                    LRAT, RPE65                                                                                                                      0.030184
  GO:0016101 diterpenoid metabolic process                                                                  LRAT, RPE65                                                                                                                      0.030184
  GO:0001523 retinoid metabolic process                                                                     LRAT, RPE65                                                                                                                      0.030184
                                                                                                                                                                                                                                             
  C, 12 weeks                                                                                                                                                                                                                                
                                                                                                                                                                                                                                             
  Term                                                                                                      Genes                                                                                                                            P-value
                                                                                                                                                                                                                                             
  GO:0045893 positive regulation of transcription, DNA-dependent                                            MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.001781
  GO:0051254 positive regulation of RNA metabolic process                                                   MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.001862
  GO:0045941 positive regulation of transcription                                                           MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.003924
  GO:0010628 positive regulation of gene expression                                                         MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.004415
  GO:0045944 positive regulation of transcription from RNA polymerase II promoter                           MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2                                                                                            0.004659
  GO:0008285 negative regulation of cell proliferation                                                      MSX1, INPPL1, PTTG1, FOXP3, IGFBP3                                                                                               0.006831
  GO:0045935 positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process   MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.007352
  GO:0051173 positive regulation of nitrogen compound metabolic process                                     MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.008442
  GO:0010557 positive regulation of macromolecule biosynthetic process                                      MSX1, VGLL2, TEAD3, FOXP3, ELL3, PAX2, RBPJL                                                                                     0.008569
  GO:0010273 detoxification of copper ion                                                                   MT1A, MT2A                                                                                                                       0.008659

GO, gene ontology.
